The global COVID-19 sample collection kits market size was valued at USD 12.9 billion in 2020 and is projected to expand at a CAGR of 3.6% during the forecast period, 2021-2028. The growth of the market is attributed to the introduction of standard procedures with the guidance of proper specimen collection of COVID-19 patients across regions.
The COVID-19 is a highly infectious disease caused by a virus called the severe acute respiratory syndrome or the SARS coronavirus. This disease was initially identified to be originated from Wuhan City, located at the Hubei Province, China as an outbreak reported of respiratory illness. The first preliminary reports about this coronavirus were submitted to World Health Organization (WHO) on December 31st, 2019. One month later, WHO announced that the COVID-19 outbreak as a pandemic and a global health emergency for the population worldwide. The last global pandemic that the world witnessed was the H1N1 influenza back in 2009.
Symptoms of the COVID-19 ranged from common cold to life threatening diseases such as lack of breadth and lower heart rate. Transmission of the COVID-19 virus occurs when people were exposed to the airborne particles which were exhaled by an infectious person. This risk of the infection gets higher when people come in close contact such as shaking hands or hugging. As a consequence, this pandemic has caused both economic and social disruptions across the globe as governments had to impose movement restriction and complete shutdown of the manufacturing industries to curb the virus spread. Schools and colleges were closed indefinitely while several companies were forced to operate at half staffs or closed down.
The report on the global COVID-19 sample collection kits market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attribute |
Details |
Report Title |
COVID-19 Sample Collection Kits Market – Global Industry Analysis, Growth, Share, Size, Trends and Forecast |
Base Year |
2020 |
Historic Data |
2018-2019 |
Forecast Period |
2021-2028 |
Segmentation |
Products (Swabs [Nasopharyngeal Swabs, Oropharyngeal Swabs, and Others], Viral Transport Media, Blood Collection Kits, and Other Consumables), Application Areas (Diagnostics and Research), and Sites of Collection (Hospitals & Clinics and Home Test) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
Key Players Covered in the Report |
Puritan Medical Products; COPAN Diagnostics; Becton, Dickinson and Company; Thermo Fisher Scientific, Inc; Laboratory Corporation of American Holdings; Lucence Diagnostics Pte Ltd; Hardy Diagnostics; Trinity Biotech; Quidel Corporation; Quest Diagnostics; Danahar Corporation; Vitagene Inc; Formlabs; HiMedia Laboratories; VIRCELL S.L; US Cotton; and Cepheid |
On the basis of products, the COVID-19 sample collection kits market is segmented into swabs, viral transport media, blood collection kits, and other consumables. The swabs segment is further divided into nasopharyngeal swabs, oropharyngeal swabs, and others. Of all these segments, the swabs segment held a leading share of the market representing above 42% in 2020 and is expected to constitute a key market share in the coming years. This segment growth is attributed primarily to the approval of a significant number of COVID-19 diagnostic products with the use of nasopharyngeal swabs. Other samples can be used from the respiratory tract which cannot be collected by the nasopharyngeal swabs.
In these scenarios, the medical team relies on the oropharyngeal swabs. Rising investment from key market players to improve their distribution and supply chain processes is another key factor driving the segment growth. For instance, in November 2020, Puritan Medical Products received funds worth USD 11.8 million for the expansion of their swab manufacturing capabilities. Additional funds were also organized by the Health Care Enhancement Act and Paycheck Protection Program.
On the basis of application areas, the market is bifurcated into diagnostics and research. The diagnostics segment held more than 65.9% of the market in 2020 and is projected to account for a large revenue share of the market in the coming years. This is contributed mainly because of the continuous approvals by the regulatory bodies to conduct diagnostic tests. As of December 2nd, 2020, the US approved 1299 tests, all conducted by the diagnostic applications.
The advanced use of swabs required for the disease diagnosis acts as a major driving factor for the segment growth. Innovations and advancement in the diagnostics segment are significantly higher than that of the research segment, which is more from a theoretical standpoint. On the other hand, the research segment is rapidly increasing its market share owing to the wide research & development activities in laboratories and universities, but the patent approval and other processes would be time consuming. However, the increase in funding towards this segment can be a key driver for the segment expansion.
On the basis of sites of collection, the COVID-19 sampling collection kits market is bifurcated into hospitals & clinics and home test. The hospitals & clinics segment held a major share of the market accounting for more than 90% of the global market in 2020 due to the exponential rise in number of hospitalizations with respect to the COVID-19 pandemic.
Meanwhile, the home tests are expected to register a moderate growth rate as the test settings are not fully developed due to lack of infrastructures. People also felt that hospitals, with their expertise, were a safer option against the coronavirus. With the pandemic started to increase daily, hospitals start adopting various devices and technology to expand and innovate their testing capabilities. However, new methods such as the “COVID-19 Immunity Profile”, an application introduced by Mybiopassport allowed people to run their blood collection tests at home.
In terms of regions, the market is classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to constitute nearly 35% of the global COVID-19 sampling collection kits market in the coming years. The USA is currently one of the most affected countries in the world with the highest number of COVID-19 cases and death. As per the US Government report, the country has already conducted over 210 million COVID-19 tests, which is considered to be one of the most single handedly tests any country has performed in the world.
Moreover, the facilities in USA are normally believed that it can process roughly 600,000 tests per day. In early March, 2021, the US Department of Defense offered a USD 52 million contract with Puritan Medical Products to innovate better supply chains of the testing kits and others devices.
On the other hand, Europe is projected to hold a large market share in the coming years owing to increasing investment from governments across the region to increase more hospitals and healthcare centers exclusively for the COVID-19 pandemic. Meanwhile, Asia Pacific is expected to register a high CAGR during the forecast period owing to the increasing number of COVID-19 patients. Countries such as India are in constant need for testing kits due to surge in COVID-19 cases due to Second wave of the pandemic.
The global COVID-19 sampling collection kits market has been segmented in terms of
Key players of the COVID-19 sampling collection kits market are Puritan Medical Products; COPAN Diagnostics; Becton, Dickinson and Company; Thermo Fisher Scientific, Inc; Laboratory Corporation of American Holdings; Lucence Diagnostics Pte Ltd; Hardy Diagnostics; Trinity Biotech; Quidel Corporation; Quest Diagnostics; Danahar Corporation; Vitagene Inc; Formlabs; HiMedia Laboratories; VIRCELL S.L; US Cotton; and Cepheid.
A significant number of well-established players have focused to innovate their products at a quicker rate. This made the market competition much more intense than usual amid government initiatives to allocate a certain expenditure to COVID-19 vaccinations and research studies. These companies increased their capacity of production of swabs with respect to their patients’ demands. Every company now focuses on the constant efforts to offer easy product distribution and transportation to all their patients besides implementing new technology.
The global COVID-19 sampling collection kits market has been segmented in terms of
Key players of the COVID-19 sampling collection kits market are Puritan Medical Products; COPAN Diagnostics; Becton, Dickinson and Company; Thermo Fisher Scientific, Inc; Laboratory Corporation of American Holdings; Lucence Diagnostics Pte Ltd; Hardy Diagnostics; Trinity Biotech; Quidel Corporation; Quest Diagnostics; Danahar Corporation; Vitagene Inc; Formlabs; HiMedia Laboratories; VIRCELL S.L; US Cotton; and Cepheid.
A significant number of well-established players have focused to innovate their products at a quicker rate. This made the market competition much more intense than usual amid government initiatives to allocate a certain expenditure to COVID-19 vaccinations and research studies. These companies increased their capacity of production of swabs with respect to their patients’ demands. Every company now focuses on the constant efforts to offer easy product distribution and transportation to all their patients besides implementing new technology.
Some other reports from this category!